Deep multi-omic phenotyping of biospecimens for immuno-oncology applications

Harnessing the power of the host immune system to treat diseases has been transformational in patient care. Physiologically relevant cellular models and biospecimens not only play a crucial role for disease diagnosis, but also for the development of such immunotherapies. Characterizing biological materials in-depth is essential for biomarker identification, characterization of a disease, molecular classification of tumors, characterization of the immune response, and evaluation of therapeutic targets. The use of advanced tools, such as high-throughput flow cytometry and genomic analysis, allow comprehensive evaluation of these complex materials.

 

Discovery Life Sciences is the global market leader in biospecimen analysis, procurement, distribution, and multi-omic services. In order to support the development of immuno-, cell, and gene therapies, they integrate their global clinical network, in-house apheresis collections, and cell expert services on Miltenyi Biotec’s flow cytometry and cell isolation platforms. This allows them to generate large-scale patient or biospecimen cohorts through the identification of specific biomarkers and donor characteristics, thereby enabling critical precision medicine strategies spanning from basic research to GMP manufacturing.

 

During this webinar, Dr. Shawn Fahl will discuss several case studies, including the immunophenotyping of 2,800 recallable leukapheresis donors, immunomodulatory receptor expression within dissociated solid tumors, and single-cell sequencing of complex tumor microenvironments.

 

Learning Objectives: